[go: up one dir, main page]

EE05473B1 - Levodopa/karbidopa/entakapooni farmatseutiline preparaat, selle valmistamise meetod ja kasutamine - Google Patents

Levodopa/karbidopa/entakapooni farmatseutiline preparaat, selle valmistamise meetod ja kasutamine

Info

Publication number
EE05473B1
EE05473B1 EEP200100716A EEP200100716A EE05473B1 EE 05473 B1 EE05473 B1 EE 05473B1 EE P200100716 A EEP200100716 A EE P200100716A EE P200100716 A EEP200100716 A EE P200100716A EE 05473 B1 EE05473 B1 EE 05473B1
Authority
EE
Estonia
Prior art keywords
preparation
entacapone
carbidopa
levodopa
pharmaceutical preparation
Prior art date
Application number
EEP200100716A
Other languages
English (en)
Estonian (et)
Inventor
Kallioinen Sari
Kervinen Lasse
Laaksonen Marja
Lintulaakso Jarmo
Niskanen Mervi
Partanen Marja
Ritala Marja
Vahervuo Kari
Virkki Matti
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8554988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05473(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of EE200100716A publication Critical patent/EE200100716A/xx
Publication of EE05473B1 publication Critical patent/EE05473B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EEP200100716A 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapooni farmatseutiline preparaat, selle valmistamise meetod ja kasutamine EE05473B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI991485A FI109453B (fi) 1999-06-30 1999-06-30 Farmaseuttinen koostumus
PCT/FI2000/000593 WO2001001984A1 (en) 1999-06-30 2000-06-29 Levodopa / carbidopa / entacapone pharmaceutical preparation

Publications (2)

Publication Number Publication Date
EE200100716A EE200100716A (et) 2003-02-17
EE05473B1 true EE05473B1 (et) 2011-10-17

Family

ID=8554988

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100716A EE05473B1 (et) 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapooni farmatseutiline preparaat, selle valmistamise meetod ja kasutamine

Country Status (42)

Country Link
US (2) US6500867B1 (xx)
EP (1) EP1189608B1 (xx)
JP (2) JP4204783B2 (xx)
KR (1) KR100905428B1 (xx)
CN (1) CN1168440C (xx)
AR (1) AR033796A1 (xx)
AT (1) ATE245417T1 (xx)
AU (1) AU765932B2 (xx)
BG (1) BG65364B1 (xx)
BR (2) BR0011867A (xx)
CA (1) CA2378469C (xx)
CO (1) CO5180579A1 (xx)
CZ (2) CZ303010B6 (xx)
DE (1) DE60004052T2 (xx)
DK (1) DK1189608T3 (xx)
EA (1) EA004503B1 (xx)
EE (1) EE05473B1 (xx)
ES (1) ES2203495T3 (xx)
FI (1) FI109453B (xx)
FR (1) FR2797587A1 (xx)
GE (1) GEP20043314B (xx)
HK (1) HK1047040B (xx)
HR (1) HRP20020088B1 (xx)
HU (1) HU230395B1 (xx)
IL (1) IL146807A (xx)
IT (1) ITMI20001450A1 (xx)
ME (1) ME00520B (xx)
MX (1) MXPA01013167A (xx)
MY (1) MY127685A (xx)
NO (2) NO330260B1 (xx)
NZ (1) NZ515780A (xx)
PE (1) PE20010399A1 (xx)
PL (1) PL197818B1 (xx)
PT (1) PT1189608E (xx)
RS (1) RS50368B (xx)
SI (1) SI1189608T1 (xx)
SK (1) SK286451B6 (xx)
TR (1) TR200103763T2 (xx)
TW (1) TWI241187B (xx)
UA (1) UA75047C2 (xx)
WO (1) WO2001001984A1 (xx)
ZA (1) ZA200109868B (xx)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
US20040180086A1 (en) * 2002-10-11 2004-09-16 Zebunnissa Ramtoola Gastro-retentive levodopa delivery form
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
WO2006051154A1 (en) 2004-11-10 2006-05-18 Orion Corporation Treatment of restless legs syndrome
AU2012216377C1 (en) * 2005-06-08 2013-10-10 Orion Corporation Oral dosage form
WO2006131591A2 (en) * 2005-06-08 2006-12-14 Orion Corporation An entacapone-containing oral dosage form
EP1901720A2 (en) * 2005-06-23 2008-03-26 Spherics, Inc. Improved dosage forms for movement disorder treatment
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
ES2545178T3 (es) 2005-07-26 2015-09-09 Bial-Portela & Ca, S.A. Derivados de nitrocatecol como inhibidores de la COMT
US8877802B2 (en) * 2005-07-28 2014-11-04 Duke Univerity Antiparkinsonian action of phenylisopropylamines
EP1948153A2 (en) * 2005-09-21 2008-07-30 Orion Corporation Treatment of symptoms of parkinson`s disease
WO2007056570A2 (en) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Levodopa compositions
WO2007069274A2 (en) * 2005-11-09 2007-06-21 Torrent Pharmaceuticals Limited Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
CN100384411C (zh) * 2006-03-17 2008-04-30 北京科信必成医药科技发展有限公司 卡左双多巴口腔崩解片
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
EP2104424A4 (en) * 2006-10-30 2011-06-15 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
US20100104634A1 (en) * 2006-12-27 2010-04-29 Mahesh Rameshwar Kalantri Pharmaceutical compositions of entacapone
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
DK2481410T3 (en) 2007-01-31 2016-10-24 Bial - Portela & Ca S A Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
NZ587168A (en) * 2008-02-06 2011-06-30 Wockhardt Research Center Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
RU2010136934A (ru) * 2008-02-06 2012-03-20 Вокхард Рисерч Сентер (In) Фармацевтические композиции энтакапона, микронизированного с сахарными спиртами
CL2009000628A1 (es) 2008-03-17 2010-04-09 Bial Portela & Companhia S A Forma cristalina de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol, composicion farmaceutica que la comprende, proceso para obtenerla y su uso para tratar trastornos del animo, enfermedad de parkinson y trastornos parkinsonianos, alteraciones gastrointestinales, entre otros.
CA2734972C (en) * 2008-08-22 2017-03-28 Wockhardt Research Centre An extended release pharmaceutical composition of entacapone or salts thereof
KR20110046555A (ko) * 2008-08-22 2011-05-04 욱크하르트 리서치 센터 레보도파, 카비도파 및 엔타카폰 또는 이의 염을 포함하는 단일 단위 경구 투여 약학 조성물
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
KR20210009441A (ko) 2009-04-01 2021-01-26 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
DK3192500T3 (da) 2009-05-19 2020-12-21 Neuroderm Ltd Sammensætninger til kontinuerlig indgivelse af dopa-decarboxylasehæmmere
WO2011075912A1 (zh) 2009-12-25 2011-06-30 台湾东洋药品工业股份有限公司 治疗帕金森氏症的医药组合物及其制备方法
CN102781424B (zh) * 2010-03-04 2016-03-30 奥赖恩公司 左旋多巴、卡比多巴和恩他卡朋用于治疗帕金森病的应用
DE102010023828A1 (de) * 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
EP3326615B1 (en) * 2010-11-15 2020-01-08 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
KR101807907B1 (ko) * 2011-04-26 2017-12-11 이노파막스, 인크. 엔타카폰의 조성물
EP2791134B1 (en) 2011-12-13 2019-09-25 BIAL - Portela & Cª S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
TR201204839A2 (tr) * 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
CN107693486A (zh) 2012-06-05 2018-02-16 纽罗德姆有限公司 包含阿朴吗啡和有机酸的组合物及其用途
AU2014229127B2 (en) * 2013-03-13 2018-04-05 Neuroderm Ltd Method for treatment of parkinson's disease
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
CA2926082C (en) 2013-10-07 2022-06-14 Impax Laboratories, Inc. Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
HRP20201948T1 (hr) 2014-03-13 2021-01-22 Neuroderm Ltd Pripravci inhibitora dopa-dekarbokilaze
EP3188725B1 (en) 2014-09-04 2020-10-28 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
WO2016101969A1 (en) 2014-12-23 2016-06-30 Pharmathen S.A. Levodopa/carbidopa/entacapone pharmaceutical preparation and method for preparing the same
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
WO2018011181A1 (en) * 2016-07-11 2018-01-18 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia
WO2018034626A1 (en) 2016-08-18 2018-02-22 İlko İlaç Sanayi Ve Ticaret Anonim Şirketi Antiparkinson tablet formulation with improved dissolution profile
WO2019145773A1 (en) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Liposomal-encapsulated formulations
NZ768098A (en) 2018-03-23 2025-12-19 Lobsor Pharmaceuticals Ab Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US12194150B2 (en) 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE4101873C2 (de) 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
US6599530B2 (en) 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus

Also Published As

Publication number Publication date
BG65364B1 (bg) 2008-04-30
HUP0202273A3 (en) 2002-11-28
UA75047C2 (en) 2006-03-15
EE200100716A (et) 2003-02-17
DE60004052T2 (de) 2004-04-15
JP4885896B2 (ja) 2012-02-29
NO330260B1 (no) 2011-03-14
BR0011867A (pt) 2002-03-05
HU230395B1 (hu) 2016-04-28
AR033796A1 (es) 2004-01-07
CA2378469A1 (en) 2001-01-11
MXPA01013167A (es) 2002-07-02
ES2203495T3 (es) 2004-04-16
DK1189608T3 (da) 2003-11-10
CZ20014636A3 (cs) 2002-05-15
PL197818B1 (pl) 2008-04-30
SI1189608T1 (en) 2004-04-30
IL146807A (en) 2006-10-05
FR2797587A1 (fr) 2001-02-23
ZA200109868B (en) 2003-05-28
BG106251A (en) 2002-08-30
HRP20020088A2 (en) 2005-10-31
NO20016203D0 (no) 2001-12-18
EA200200106A1 (ru) 2002-06-27
CO5180579A1 (es) 2002-07-30
KR20020010155A (ko) 2002-02-02
CA2378469C (en) 2009-10-06
ITMI20001450A0 (it) 2000-06-28
PT1189608E (pt) 2003-12-31
AU765932B2 (en) 2003-10-02
SK19232001A3 (sk) 2002-06-04
NO20016203L (no) 2002-02-25
YU92501A (sh) 2004-09-03
US6797732B2 (en) 2004-09-28
US20030017201A1 (en) 2003-01-23
TR200103763T2 (tr) 2002-04-22
ME00520B (me) 2011-10-10
HRP20020088B1 (hr) 2007-05-31
NO20110090L (no) 2002-02-25
EP1189608A1 (en) 2002-03-27
CZ303010B6 (cs) 2012-02-29
JP4204783B2 (ja) 2009-01-07
ITMI20001450A1 (it) 2001-12-28
CZ304416B6 (cs) 2014-04-23
ATE245417T1 (de) 2003-08-15
TWI241187B (en) 2005-10-11
SK286451B6 (sk) 2008-10-07
CN1168440C (zh) 2004-09-29
JP2008156373A (ja) 2008-07-10
HK1047040A1 (en) 2003-02-07
US6500867B1 (en) 2002-12-31
BRPI0011867B8 (pt) 2021-05-25
RS50368B (sr) 2009-11-10
GEP20043314B (en) 2004-02-10
FI991485L (fi) 2000-12-31
WO2001001984A1 (en) 2001-01-11
CN1358090A (zh) 2002-07-10
FI991485A0 (fi) 1999-06-30
NZ515780A (en) 2004-06-25
HK1047040B (zh) 2005-04-29
HUP0202273A2 (en) 2002-10-28
FI109453B (fi) 2002-08-15
BRPI0011867B1 (pt) 2019-01-08
KR100905428B1 (ko) 2009-06-30
MY127685A (en) 2006-12-29
DE60004052D1 (de) 2003-08-28
EP1189608B1 (en) 2003-07-23
PL352775A1 (en) 2003-09-08
AU5830600A (en) 2001-01-22
JP2003503454A (ja) 2003-01-28
PE20010399A1 (es) 2001-04-10
EA004503B1 (ru) 2004-04-29

Similar Documents

Publication Publication Date Title
EE05473B1 (et) Levodopa/karbidopa/entakapooni farmatseutiline preparaat, selle valmistamise meetod ja kasutamine
EE9700310A (et) N-propargüül-1-aminoindaani R-enantiomeeri, selle soolade ja kompositsioonide kasutamine
EE04417B1 (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm, selle valmistamise meetod ja kasutamine
EE03676B1 (et) Mullpakend, selle valmistamise meetod ja mullpakendi kasutamine
NO980628D0 (no) Gjenstand med mikroorganismeavvisende belegg, dens fremstilling og anvendelse
FI962927A7 (fi) Tetrasykliinijohdannaisia, valmistusmenetelmä ja käyttö
EE04452B1 (et) Farmatseutiliselt aktiivne morfolinool ja selle kasutamine
EE200300581A (et) Karboksamiid-asendatud fenüüluurea derivaadid ja nende kasutamine, ravim ja selle valmistamismeetod
EE05267B1 (et) Antraniilhappe amiidid, nende kasutamine ja farmatseutiline preparaat
EE04565B1 (et) Adamantaani derivaadid, nende saamine ja kasutamine
NO975513D0 (no) 3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse som legemiddel
IS6181A (is) Ein- og tvíataðgengnar 3-própýl-gamma-amínósmjörsýrur
IS5353A (is) Asýl-píperasínil-pýrimídínafleiður, framleiðsla og notkun þeirra sem lyfja
EE200100314A (et) Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine
FI972264L (fi) Betaiinituote, menetelmä sen valmistamiseksi, ja sen käyttö
EE05187B1 (et) Hirudiini prekursor, selle kasutamine ja meetod Leu-hirudiini valmistamiseks
EE200000099A (et) Antimükootiline kompositsioon, selle kasutamine ja valmistamismeetod ning antimükootiline toode
EE9800075A (et) Kombineeritud ravimpreparaat, selle kasutamine ja meetod selle valmistamiseks
EE04902B1 (et) Mikrograanul, selle valmistamismeetod ja farmatseutiline preparaat
EE04770B1 (et) Tritsüklilised delta3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod
IT1283489B1 (it) Ammidi di alfa-amminoacidi,loro preparazione e loro impiego terapeutico
EE03798B1 (et) Söödalisandi valmistamise meetod, söödalisand ja selle kasutamine
EE04260B1 (et) Farmatseutiline kompositsioon, selle valmistamisemeetod ja kasutamine
EE200200096A (et) IREN-valk, selle valmistamine ja kasutamine
EE200000018A (et) 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name